DirectView Selected to Provide Surveillance Systems for LBU Lighting's Nine Retail Locations in Florida

Installation contract projected value is in excess of $100,000

 NEW YORK and WEST PALM BEACH, Florida, - (http://www.financialnewsmedia.com News Alert) - DirectView Holdings, Inc. (OTC: DIRV) ("DirectView" or the "Company"), a company focused on ownership and management of leading video and security technology companies, today announced that it has been selected by LBU Group ("LBU"), to provide complete surveillance systems for its nine retail locations throughout Florida. DirectView will install a full array of surveillance cameras and NVR recording equipment at each location as well as a remote monitoring center at LBU's headquarters in Deerfield Beach, Florida. The full installation contract is projected at in excess of $100,000. In addition, DirectView has received a ten year ongoing system maintenance agreement.

Mr. Jake Gersowsky, CFO of LBU, commented, "As an established retail chain, we know that having the highest level of security and surveillance at our locations helps us to provide an exceptional shopping experience for our customers while minimizing loss from theft and creating a safer workplace for our employees. We selected DirectView for their extensive expertise and top notch products and we look forward to a long lasting relationship with them as we grow our company in the years to come." Roger Ralston, CEO and Chairman of DirectView, stated "We are excited to have been chosen by LBU to provide our comprehensive surveillance systems for all of their Florida locations. Our systems provide retail organizations with extensive monitoring for theft prevention as well as customer and employee safety which is critical in today's environment. We look forward to building a long lasting relationship with LBU at their current locations and as they expand in the future."

About LBU Lighting, Inc.

The first Light Bulbs Unlimited store in Florida opened in Fort Lauderdale in 1987 and immediately became a bright point on the South Florida landscape. Many of the first visitors were motivated more by curiosity than need, and most were amused by the concept that anyone could make a living by just selling light bulbs. Our showrooms now house an eclectic collection of modern and contemporary lighting fixtures and fans, elegantly displayed on custom-built ceiling clouds and wall panels. Today the LBU Lighting consists of nine established locations across South Florida, Orlando, Naples and the Treasure Coast. For more information please visit http://www.lbulighting.com.

About DirectView Holdings, Inc.

DirectView Holdings, Inc., together with its subsidiaries, provides video surveillance solutions and teleconferencing products and services to businesses and organizations. The company operates in two divisions, Security (Video Surveillance) and Video Conferencing. The Security division offers technologies in surveillance systems providing onsite and remote video and audio surveillance, digital video recording, and services. It also sells and installs surveillance systems; and sells maintenance agreements. The company sells its products and services in the United States and internationally through direct sales force, referrals, and its Websites. The Video Conferencing division offers teleconferencing products and services that enable clients to conduct remote meetings by linking participants in geographically dispersed locations. It is involved in the sale of conferencing services based upon usage, the sale and installation of video equipment, and the sale of maintenance agreements. This division primarily provides conferencing products and services to numerous organizations ranging from law firms, banks, high tech companies and government organizations. For more information visit our website at http://www.DirectView.com and connect with us on Twitter, LinkedIn, Facebook, and Google+.

Cautionary Statement Regarding Forward Looking Statements

Forward Looking Statements: This press release contains forward-looking statements that involve a number of risks and uncertainties, including statements regarding the outlook of the Company's business and results of operations. By nature, these risks and uncertainties could cause actual results to differ materially from those indicated. Generally speaking, any statements using terms such as "will," "expect," "anticipate," or "may," or which otherwise predict or address future results or events, are likely to contain forward-looking statements. It is important to note that actual results may differ materially from what is indicated in any forward-looking statement. Readers should consider any forward-looking statements in light of factors that could cause actual results to vary. These factors are described in our filings with the SEC, and readers should refer to those filings, including Risk Factors described in those filings, in connection with any forward-looking statements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:
DirectView Holdings, Inc.
Roger Ralston
+1-212-858-9100 EXT. 111
http://www.DirectView.com
IR@DirectView.com


SOURCE DirectView Holdings, Inc.

FN Media Group LLC (FNMG) owns and operates FinancialNewsMedia.com (FNM) which is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNMG is NOT affiliated in any manner with any company mentioned herein. FNMG and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.  For current services performed FNMG was compensated three thousand five hundred dollars for Direct View Holdings, Inc. news coverage by the company.  FNMG HOLDS NO SHARES OF Direct View Holdings, Inc.

 This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.  

National Waste Management Holdings Inc. Acquires Waste Recovery Enterprises LLC

HERNANDO, Florida, - (http://www.financialnewsmedia.com News Alert) - National Waste Management Holdings, Inc., (OTCQB: NWMH) announces that it has completed its acquisition of Waste Recovery Enterprises LLC located in Bainbridge, New York for $250,000 and 2.75 million restricted shares. The definitive membership interest purchase agreement provides for the purchase of all of the outstanding membership interest of Waste Recovery Enterprises, LLC by National Waste Management Holdings, Inc. ("National Waste"). The completed acquisition is expected to generate revenue for National Waste in excess of $1,500,000 annually with gross profit margins of approximately 45%.

 Waste Recovery Enterprises operates a permitted waste processing and disposal facility in Bainbridge, New York, about 200 miles northwest of New York City. The facility has been in continuous operation since 1998 and principally serves the northeastern U.S. industrial and residential markets.

"The addition of this facility to National Waste's family of permitted facilities provides us with a northeastern presence and an exceptional platform to better serve and expand into key waste markets," says National Waste's CEO, Louis Paveglio. "Waste Recovery's facility will allow us to enhance our service offering, bid and win more work, and increase penetration of key accounts."

"The acquisition of Waste Recovery is consistent with our business strategy to acquire facilities that increase our geographic footprint, augment services to existing customers, and attract new customers in under serviced markets," added Jeff Chartier, President of National Waste.

About National Waste Management Holdings Inc.:

National Waste Management Holdings Inc., is a growing and emerging vertically integrated solid waste management company with a concentration on C&D collection, hauling and recycling. National Waste services Florida's west coast and upstate New York and is a distinguished leader in solid waste services. More information may be found at the Company's website: http://www.nationalwastemgmt.com.

This release contains certain statements that are, or may be deemed to be, forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934, and are made in reliance upon the protections provided by such Acts for forward-looking statements.  We have identified forward-looking statements by using words such as "expect," "believe," and "should." Although we believe our expectations are reasonable, our operations involve a number of risks and uncertainties that are beyond our control, and these statements may turn out not to be true. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company's Form SEC filings.

Investor Relations:
Natalya Rudman
 Crescendo Communications, LLC
 +1-(212)671-1020, Ext:304
nwmh@crescendo-ir.com


SOURCE National Waste Management Holdings Inc

FN Media Group LLC (FNMG) owns and operates FinancialNewsMedia.com (FNM) which iis a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNMG is NOT affiliated in any manner with any company mentioned herein. FNMG and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.  For current services performed FNMG was compensated three thousand five hundred dollars for National Waste Management Holdings Inc. news coverage by a non-affiliated third party.  FNMG HOLDS NO SHARES OF National Waste Management Holdings Inc.

 This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.

MagneGas Subsidiary Lands Largest Single Customer in Company History

MagneGas Subsidiary E.S.S.I. Closes Major Sale with Over $400,000 in Annual Recurring Revenue Expected from Single Customer

TAMPA, Florida, - (http://www.financialnewsmedia.com News Alert) - MagneGas Corporation (NASDAQ: MNGA) a leading technology company that counts among its inventions a patented process that converts liquid waste into MagneGas2® fuel, announced today that its wholly owned gas distribution subsidiary Equipment Sales and Services, Inc. ("E.S.S.I") has received confirmation that a major industrial company is moving all of their welding gas and related product orders to E.S.S.I.  The Company estimates that their annual sales from this one customer will exceed $400,000. 

E.S.S.I. distributes MagneGas® fuel, industrial gases and related products and was acquired by MagneGas Corporation as a wholly owned subsidiary in late 2014. They have been pursuing this new customer for over 12 months through various demonstrations and executive meetings. The new customer has indicated they will be purchasing all of their industrial gases and welding products throughout the year from E.S.S.I and their initial orders have been placed and delivered. This customer previously ordered their gases and welding products from an international multi-billion dollar MagneGas competitor.  The customer stated that they are switching to E.S.S.I. due to the superior customer service and exclusive access to MagneGas2® fuel.

"This is a significant win for our Company. We believe it proves the model that MagneGas2 can be used as a major door opener to these previously unavailable large customers. In addition, we have been hearing time and again that poor customer service from our competitors, combined with our exclusive MagneGas2 product offering is closing sales. We look forward to continue to pursue our sales strategy through our national expansion plans," commented Ermanno Santilli, CEO, MagneGas Corporation.

The MagneGas IR App is now available for free in Apple's App Store for the iPhone or iPad http://bit.ly/AfLYww and at Google Play http://bit.ly/Km2iyk for Android mobile devices.

To be added to the MagneGas investor email list, please email pcarlson@kcsa.com with MNGA in the subject line.

About MagneGas Corporation 

MagneGas® Corporation (NASDAQ: MNGA). The Company owns a patented process that converts various liquid wastes into hydrogen based fuels. These fuels can be used as a replacement to natural gas or for metal cutting. The Company's testing has shown the fuels are faster, cleaner and more productive than other alternatives on the market. They are also cost effective and safe to use with little changeover costs.  The Company currently sells MagneGas® into the metal working market as a replacement to acetylene. 

The MagneGas fuel production systems can be set-up locally using various types of feedstock. The Company believes this flexibility can give them an advantage in the Government/Military marketplace as fuels can be manufactured on site from raw materials found locally worldwide and eliminates the time and expense of shipping to the specific military theater. The Company is planning to establish joint ventures with third parties to construct these supply facilities worldwide.

The Company also sells equipment for the sterilization of bio-contaminated liquid waste for various industrial and agricultural markets. In addition, the Company is developing a variety of ancillary uses for MagneGas® fuels utilizing its high flame temperature for co-combustion of hydrocarbon fuels and other advanced applications.  For more information on MagneGas®, please visit the Company's website at http://www.MagneGas.com.

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements as defined within Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.  These statements relate to future events, including our ability to raise capital, or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The Company is currently using virgin vegetable oil to produce fuel while it configures its systems to properly process waste within local regulatory requirements.

For a discussion of these risks and uncertainties, please see our filings with the Securities and Exchange Commission. Our public filings with the SEC are available from commercial document retrieval services and at the website maintained by the SEC at http://www.sec.gov.


Investor Contacts:
KCSA Strategic Communications
Philip Carlson / Brad Nelson
+1-212-896-1233 / +1-212-896-1217
pcarlson@kcsa.com / bnelson@kcsa.com

SOURCE MagneGas Corporation


FN Media Group LLC (FNMG) owns and operates FinancialNewsMedia.com (FNM) which iis a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNMG is NOT affiliated in any manner with any company mentioned herein. FNMG and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.  For current services performed FNMG was compensated three thousand five hundred dollars for MagneGas Corp. news coverage by a non-affiliated third party.  FNMG HOLDS NO SHARES OF MagneGas Corp.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.
 

Q BioMed Inc. is Pleased to Announce a Letter-Of-Intent to Exclusively In-License and Ultimately Acquire the Assets of Mannin Research Inc.

Technology asset well positioned to be a First-In-Class molecule for the treatment of Glaucoma, a leading cause of blindness in the US and around the world.

 NEW YORK, - (http://www.financialnewsmedia.com News Alert) - Q BioMed Inc (OTC: QBIO), a biotechnology acceleration and development company is pleased to announce a Letter of Intent to in-license and ultimately acquire the assets of Mannin Research Inc.

Mannin Research Inc, is a biotechnology company leading the development of a new class of vascular therapeutics.  The drug development program at Mannin is led by Mannin's Chief Scientific Officer, Dr. Susan E. Quaggin, Chief of the Division of Nephrology and Director of the Feinberg Cardiovascular Research Institute at Northwestern University in Chicago. 

Utilizing a proprietary research platform, only recently published (September 2014) in the Journal of Clinical Investigations, this technology is addressing the need for a new class of drugs to treat diseases such as Glaucoma and Cystic Kidney disease.  Our primary target indication is for a first-in-class therapeutic eye-drop for the treatment of Glaucoma in adults and children.

The global market for Glaucoma therapeutics is one of the largest segments of the $23 billion global ophthalmology market.  There are 60 million people worldwide suffering from Glaucoma.  It is projected that the total population suffering from Glaucoma will grow to 80 million by 2020 (W.H.O 2010). Our lead candidate, MAN-01, will address this market as a first-in-class drug that treats abnormal vessels within the eye, thereby treating Glaucoma at its root causes.  There have been no new class drugs developed for Glaucoma for 20 years, since Pfizer introduced Xalatan (latanaprost).

There is no cure for Glaucoma and new therapeutics are highly sought after. Current therapies and surgical procedures are not optimally effective, are painful and not well tolerated by patients.

Intra-Ocular Pressure (IOP) is caused by abnormal flow of clear fluid within the eye, causing irreversible damage to the eye, ultimately leading to blindness. A specialized blood vessel, the 'Schlemm's canal' is the major drainage pathway for fluid to escape from the front of the eye. Glaucoma can occur when this canal is either blocked or from a birth defect, resulting in a small or absent Schlemm's canal.

We are developing a unique molecule delivered in an easy-to-administer eye drop designed to repair the normal flow of fluid in the eye resulting in the reduction of IOP, one of the main causes of Glaucoma.  Our platform is both unique and first-in-class and we are the only drug company targeting this mechanism of action.

Our estimates and market research has shown that demand for treatments in this sector is fairly in-elastic. The cost for treatment would be approximately $1000 per patient per year.  Based on a 5% sales growth per year and a conservative market penetration of 10%, revenues could exceed $9 billion over the life of the patent. A more aggressive estimate of 30% could yield up to $29 billion over the life of the patent. 

We expect to be conducting our first-in-human clinical trials by 2017.  In addition, a deep pipeline of novel therapeutics can be developed from this research platform developed and led by Dr. Quaggin, which would treat a spectrum of vascular diseases. 

"We are extremely pleased to have made the first, of what we believe, will be many exciting steps towards a well-diversified and highly valued portfolio of innovative technology assets to fall under the Q BioMed umbrella," said Denis Corin, CEO of Q BioMed Inc. "We are excited to welcome the Mannin team, including Mannin's CEO, Dr. George Nikopoulos, and CSO Dr. Susan Quaggin to the Q Family and look forward to developing an important and highly sought after therapy for this debilitating disease."

About Dr. Susan E. Quaggin, Chief Scientific Officer, Mannin Research Inc.

Susan Quaggin, MD graduated from the Faculty of Medicine at the University of Toronto in 1988 and received her specialty degree in Internal Medicine in 1992. She completed her sub-specialty training in Nephrology in 1993 at U of T and did a post-doctoral fellowship at Yale University where she studied the genetic basis of kidney development.

In 1997, she returned to Toronto to do a second post-doctoral fellowship in mouse genetics in the laboratory of Janet Rossant. From 1997 until 2012, she was at the University of Toronto where she was a Senior Scientist at the Samuel Lunenfeld Research Institute, a practicing Nephrologist at St. Michael's Hospital and the Gabor-Zellerman Professor in Renal Medicine.

Quaggin has served as an elected councilor of the American Society for Clinical Investigation (ASCI), is a member of the ISN executive Council and was elected to the American Association of Physicians (AAP) in 2013. She received the Kidney Foundation of Canada 2009 Award for Research, a Finnish Distinguished Professorship in 2012 and the Alfred Newton Richards Award for Basic Science from the International Society of Nephrology in 2013. In addition, Quaggin sits on the editorial boards of several journals, and has organized a number of international renal and vascular meetings.

In January 2013, Quaggin joined Northwestern University Feinberg School of Medicine as the Charles Horace Mayo Professor of Medicine, where she serves as the director of the Feinberg Cardiovascular Research Institute (FCVRI) and chief of the Division of Nephrology and Hypertension.

Quaggin's research program focuses on genetic pathways required to establish and maintain the integrity of microvascular beds including the glomerular filtration barrier - a highly selective filter that separates the blood from the urinary space. To understand the pathways and interactions between perivascular cells and the endothelium, her research team has developed a number of genetic models that permit cell and time-specific manipulation of gene expression.

About Q BioMed Inc.

Q BioMed Inc. "Q" is a biomedical acceleration and development company. We are focused on acquiring companies and biomedical assets. Q is dedicated to providing these target companies and assets, strategic resources, developmental support, and expansion capital to ensure they meet their developmental potential enabling them to provide products to patients in need‏.

Forward-Looking Statements:

This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Contact:

Denis Corin
CEO
Q BioMed Inc
+1-888-357-2435

George N. Nikopoulos
CEO
Mannin Research Inc.
+1-416-306-2853
SOURCE Q BioMed Inc


FN Media Group LLC (FNMG) owns and operates FinancialNewsMedia.com (FNM) which iis a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNMG is NOT affiliated in any manner with any company mentioned herein. FNMG and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.  For current services performed FNMG was compensated five thousand dollars for Q BioMed Inc. news coverage by a non-affiliated third party.  FNMG HOLDS NO SHARES OF Q BioMed Inc. .

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.

CES Synergies Begins Interior Demolition on Building 603 at Naval Air Station Pensacola

CRYSTAL SPRINGS, Fla., - (http://www.financialnewsmedia.com News Alert) -CES Synergies, Inc. (OTC: CESX) ("CES" or the "Company"), a full service environmental, asbestos abatement and demolition company, announced today that its subsidiary, Cross Environmental Services, Inc., was awarded a contract earlier this year valued at approximately $450,000 for demolition activities that are now set to commence on building 603 at Naval Air Station Pensacola.  The building is a four-story 240,000 square foot office complex that is undergoing significant renovation.  The third floor of the building is mission critical and will be renovated in phases to ensure that this area remains open for business.  The other three floors will be conventionally renovated by CES without service interruption.

The scope of services awarded to CES includes partition demolition, removal of mechanical systems, demolition of electrical components, as well as removal of certain exterior components including ladders, canopies, and railings.  The Prime Contractor is Orocon-Carothers, a joint venture between Orocon Construction, LLC and Carothers Construction, Inc.

John Tostanoski, CEO of CES Synergies, commented, "CES is pleased to continue our relationship with Carothers and we look forward to working with Orocon as well.  We know from previous experience how critical the projects at Naval Air Station Pensacola can be, and believe our skills and experience are ideally suited to this project."

About CES Synergies Inc.

CES Synergies, Inc., through its subsidiary, Cross Environmental Services, Inc., is a specialty environmental services company providing quality environmental contracting solutions, demolition and remediation services to commercial and industrial customers, as well as federal, state and municipal entities. More information may be found at the Company's website: www.crossenv.com.

SAFE HARBOR STATEMENT: This press release may contain "forward-looking statements" that are made pursuant to the "safe harbor" provisions as defined within the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words including "anticipates," "believes," "intends," "estimates," and similar expressions. These statements are based upon management's current expectations as of the date of this press release. Such forward-looking statements may include statements regarding the Company's future financial performance or results of operations, including expected revenue growth, cash flow growth, future expenses and other future or expected performances. The Company cautions readers there may be events in the future that the Company is not able to accurately predict or control and the information contained in the forward-looking statements is inherently uncertain and subject to a number of risks that could cause actual results to differ materially from those indicated in the forward-looking statements. Further information on these and other potential factors that could affect the Company's financial results is included in the Company's filings with the SEC.

Investor Relations:
Natalya Rudman
Crescendo Communications, LLC
+1(212) 671-1020, Ext: 304
cesx@crescendo-ir.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/ces-synergies-begins-interior-demolition-on-building-603-at-naval-air-station-pensacola-300139754.html

SOURCE CES Synergies, Inc.

FN Media Group LLC (FNMG) owns and operates FinancialNewsMedia.com (FNM) which iis a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNMG is NOT affiliated in any manner with any company mentioned herein. FNMG and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.  For current services performed FNMG was compensated three thousand five hundred dollars for CES Synergies, Inc. news coverage by a non-affiliated third party.  FNMG HOLDS NO SHARES OF CES Synergies, Inc.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.

Pressure BioSciences and the Institute of Bioinformatics Announce Comprehensive Two Year Collaboration

One of India's Most Prestigious Not-for-Profit Scientific Research Organizations to Incorporate PBI's Patented PCT Platform in their Search for Molecular Biomarkers in a Number of Human Diseases and Disorders, Including Cancer and Stroke

 SOUTH EASTON, Mass, - (http://www.financialnewsmedia.com News Alert) - Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company"), a leader in the development and sale of broadly enabling pressure cycling technology ("PCT")-based sample preparation solutions to the worldwide life sciences industry,  today announced it has entered into a two-year collaboration with the Institute of Bioinformatics ("IOB") in Bangalore, India. The IOB is one of the most prestigious not-for-profit scientific research centers in India, and one of the more highly regarded proteomic research organizations worldwide. The IOB staff, which includes dozens of scientists with advanced degrees, have published several hundred scientific papers over the past decade, many with a strong focus in the areas of proteomics, genomics, and metabolomics.

The Founder and Director of the IOB is Akhilesh Pandey M.D., Ph.D. Currently, Dr. Pandey is a Professor at the Institute of Genetic Medicine and the Departments of Biological Chemistry, Oncology, and Pathology at the Johns Hopkins School of Medicine.  Dr. Pandey has received numerous prestigious honors and awards during his career, including, most recently, the Era of Hope Scholar Award by the United States Department of Defense.  This award is "intended for exceptionally talented, early-career scientists who have demonstrated that they are the best and the brightest in their field(s) through extraordinary creativity, vision, and productivity, and who have shown a strong potential for leadership in the breast cancer community as well as a vision for the eradication of breast cancer."

Dr. Pandey commented: "The preparation of samples for analysis is a crucial step in all research studies worldwide aimed at finding biomarkers for the detection, control, prevention, and/or cure of human diseases and disorders.  The IOB has modern, well-equipped facilities; however, we are well aware that the quality of results from our state-of-the-art instruments depends to a great extent on the quality and uniformity of the preparation of the samples being analyzed. Consequently, we are always searching for better, higher quality sample preparation methods that can help us process a diverse set of samples ranging from tissue biopsies to bacterial extracts.  This is how we met our colleagues at PBI, learned about the power of their PCT platform, and subsequently purchased our first PCT instrument."

Dr. Harsha Gowda, head of the proteomics program at the IOB, said: "For much of the past year, we have evaluated the PCT platform in our laboratories. We have used it extensively for preparing protein samples from paraffin-embedded biopsy tissue sections for mass spectrometry-based analysis. Early results from this very robust platform are encouraging and exciting. Consequently, we were pleased to enter into a formal, two-year collaboration with our colleagues at PBI.  During this time, we will use the PCT platform as the front-end, sample preparation method to many universally-used analytical instruments, such as mass spectrometers and third generation DNA sequencers.  Based on our results to date, we believe the PCT platform may prove to be advantageous as a sample preparation method to researchers worldwide, and perhaps also necessary for many other applications as well."

Mr. Richard T. Schumacher, President and CEO of PBI, said: "We are honored to work with such a worldwide respected scientist as Dr. Pandey. We are further honored to collaborate with Dr. Gowda and his colleagues at the IOB. We believe there are as many as 500,000 researchers around the world working with biological samples, many of whom use the same kinds of instruments (e.g., mass spectrometers, DNA sequencers, HPLCs, etc.) as those used by scientists at the IOB. These researchers are potential future users of the PCT platform. We believe the results generated at the IOB will help show the clear advantages offered by the PCT platform when this powerful, patented technology is used in the search for biomarkers.  We believe that such data, coming from a research institute with the worldwide reputation of the IOB, could have the profound effect of helping to change the PCT platform from a "want to have" to a "have to have" sample preparation system for biological research laboratories, in India and around the world."         

About the Institute of Bioinformatics

The Institute of Bioinformatics is a not-for-profit research organization engaged in biomedical research. Located in Bangalore, India, it was established in May 2002. Bangalore is a prime center for research and development and is the hub of both information technology and biotechnology in India. The Institute of Bioinformatics is a multidisciplinary systems biology research institute where scientists combine cutting-edge experimental methods in genomics, proteomics, and metabolomics with advanced computational biology, to investigate biomarkers and therapeutic targets of various diseases, including cancer.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. ("PBI") (OTCQB: PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, we have installed over 250 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. Our primary application development and sales efforts are in the biomarker discovery and forensics areas. Customers also use our products in other areas, such as drug discovery & design, bio-therapeutics characterization, soil & plant biology, vaccine development, histology, and forensic applications.     

Forward Looking Statements

Statements contained in this press release regarding PBI's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking'' statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2014, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

For more information about PBI and this press release, please click on the following website link: http://www.pressurebiosciences.com        
Please visit us on Facebook, LinkedIn, and Twitter

Investor Contacts:                                                

Richard T. Schumacher, President & CEO   
Pressure BioSciences, Inc.   
Nathan P. Lawrence, Ph.D. VP of Marketing and Sales    
+1(508) 230-1828 (T)


To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/pressure-biosciences-and-the-institute-of-bioinformatics-announce-comprehensive-two-year-collaboration-300133456.html

SOURCE Pressure BioSciences, Inc.

FN Media Group LLC (FNMG) owns and operates FinancialNewsMedia.com (FNM) which is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNMG is NOT affiliated in any manner with any company mentioned herein. FNMG and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.  For current services performed FNMG was compensated two thousand five hundred dollars for Pressure BioSciences, Inc. news coverage by a non-affiliated third party.  FNMG HOLDS NO SHARES OF Pressure BioSciences, Inc.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements. 

Nascent Biotech Achieves Two Key Milestones in Development of its Novel Brain Cancer Treatment

SAN DIEGO, - (http://www.financialnewsmedia.com News Alert) - Nascent Biotech, Inc. (OTC: NBIO). - Since March of 2014 Nascent has raised $2.1 million which has been used to advance the development of their core product, Pritumumab, to support the filing of an Investigational New Drug exemption (IND).  Pritumumab is a fully human monoclonal antibody being developed initially for the treatment of malignant and non malignant Gliomas.

One of the biggest challenges in the development of any antibody product is to show that it can be manufactured, at appropriate scale, to clinical grade and in sufficient quantity for human trials.  We have attained this goal and manufactured more than enough product to complete our initial Phase 1/Phase 2 human trials on Brain Cancers, with more than adequate amounts left over to initiate trials in other epithelial cancers such as breast, lung, colon and pancreas.  Pritumumab is unique in its ability to react strongly with all these major malignancies.    

An additional challenge is to understand the toxicity profile.  We have completed a toxicology study, in compliance with FDA guidance, and we have demonstrated no in life toxicities in the two species studied (Monkey and Rat). 

Another significant milestone worth noting is that the FDA granted Nascent Biotech an Orphan Drug Designation for Gliomas (brain cancer).  "This will give us market exclusivity for a period of 7 years after the drug is approved" say's Nascent President Sean Carrick.

About Nascent Biotech, Inc.: Nascent Biotech, Inc is a clinical-stage biotech company engaged in the development of monoclonal antibodies to be used in the treatment of various cancers.  Its products are not commercially available. For further information please visit our website www.nascentbiotech.com.

Safe Harbor: Statements in this press release about our future expectations constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995.  Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results.  These risks and uncertainties include, without limitation, Nascent Biotech Inc's ability to target the medical professionals; Nascent Biotech Inc's ability to raise capital; as well as other risks.  Additional information about these and other factors may be described in the Nascent Biotech Inc's Form 10, filed on October 28, 2014, and future filings with the Securities and Exchange Commission.  The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

Contact Information:
Nascent Biotech, Inc.
Sean Carrick
President
+1-772-713-0541
sean.carrick@nascentbiotech.com
www.nascentbiotech.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nascent-biotech-achieves-two-key-milestones-in-development-of-its-novel-brain-cancer-treatment-300128069.html

SOURCE Nascent Biotech Inc.

FN Media Group LLC (FNMG) owns and operates FinancialNewsMedia.com (FNM) which is a third party publisher that disseminates electronic information through multiple online media channels. FNMG's intended purposes are to deliver market updates and news alerts issued from private and publicly trading companies as well as providing coverage and increased awareness for companies that issue press to the public via online newswires. FNMG and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. The companies that are discussed in this release may or may not have approved the statements made in this release. Information in this release is derived from a variety of sources that may or may not include the referenced company's publicly disseminated information. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. While this information is believed to be reliable, such reliability cannot be guaranteed. FNMG disclaims any and all liability as to the completeness or accuracy of the information contained and any omissions of material fact in this release. This release may contain technical inaccuracies or typographical errors. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. Investment in the securities of the companies discussed in this release is highly speculative and carries a high degree of risk. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. This release is not without bias, and is considered a conflict of interest if compensation has been received by FNMG for its dissemination. To comply with Section 17(b) of the Securities Act of 1933, FNMG shall always disclose any compensation it has received, or expects to receive in the future, for the dissemination of the information found herein on behalf of one or more of the companies mentioned in this release. For current services performed FNMG has been compensated three thousand four hundred dollars for Nascent Biotech Inc.  news coverage by a non-affiliated third party.  FNMG HOLDS NO SHARES OF Nascent Biotech Inc.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.